We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+4.84%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.83%
AUM
$1.58B
AUM Growth
+$210M
Cap. Flow
+$71.1M
Cap. Flow %
4.5%
Top 10 Hldgs %
18.14%
Holding
221
New
32
Increased
92
Reduced
20
Closed
27

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$12.6M
2
PIII icon
P3 Health Partners
PIII
+$10.1M
3
MRVI icon
Maravai LifeSciences
MRVI
+$9.23M
4
NARI
Inari Medical, Inc. Common Stock
NARI
+$8.99M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$8.85M

Top Sells

Rank Stock Value
1
AMRS
Amyris Inc.
AMRS
+$13M
2
DMTK
DermTech, Inc. Common Stock
DMTK
+$12.9M
3
OSH
Oak Street Health, Inc.
OSH
+$11.8M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$9.93M
5
DNA icon
Ginkgo Bioworks
DNA
+$8.89M

Sector Composition

Rank Sector Weight
1 Healthcare 30.22%
2 Technology 18.11%
3 Financials 10.26%
4 Industrials 8.95%
5 Consumer Discretionary 7.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
51
Guardant Health
GH
$22.6B
$11.2M 0.71%
112,213
+17,850
+19% +$1.85M
ASML icon
52
ASML
ASML
$669B
$10.4M 0.66%
13,051
+5,337
+69% +$4.24M
CZR icon
53
Caesars Entertainment
CZR
$6.14B
$10.2M 0.65%
109,572
– –
MXCT icon
54
MaxCyte
MXCT
$126M
$10.1M 0.64%
986,301
+6,179
+0.6% +$66.4K
VERV
55
DELISTED
Verve Therapeutics
VERV
$10M 0.63%
271,589
+139,289
+105% +$5.85M
LRCX icon
56
Lam Research
LRCX
$390B
$9.95M 0.63%
138,320
+31,980
+30% +$2M
AMRC icon
57
Ameresco
AMRC
$1.36B
$9.8M 0.62%
120,369
+11,588
+11% +$927K
NARI
58
DELISTED
Inari Medical, Inc. Common Stock
NARI
$9.58M 0.61%
+104,932
New +$8.99M
MRVI icon
59
Maravai LifeSciences
MRVI
$919M
$9.55M 0.6%
+227,823
New +$9.23M
RRX icon
60
Regal Rexnord
RRX
$11.9B
$9.23M 0.58%
54,242
+10,745
+25% +$1.7M
MS icon
61
Morgan Stanley
MS
$340B
$9.08M 0.57%
92,500
+2,500
+3% +$249K
ISEE
62
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.02M 0.57%
+539,730
New +$8.85M
APO icon
63
Apollo Global Management
APO
$73.4B
$8.93M 0.57%
123,300
+48,300
+64% +$3.48M
ABNB icon
64
Airbnb
ABNB
$107B
$8.76M 0.55%
52,639
+45,835
+674% +$8.07M
AVGOP
65
DELISTED
Broadcom Inc. 8.00% Mandatory Convertible Preferred Stock, Series A
AVGOP
– –
0
– –
VRTX icon
66
Vertex Pharmaceuticals
VRTX
$126B
$8.41M 0.53%
+38,287
New +$7.45M
VTGN icon
67
VistaGen Therapeutics
VTGN
$12.8M
$8.36M 0.53%
142,936
+50,058
+54% +$3.26M
OMIC
68
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$8.34M 0.53%
24,034
+2,374
+11% +$920K
CRWD icon
69
CrowdStrike
CRWD
$218B
$8.28M 0.52%
161,820
+49,324
+44% +$3M
EXAS
70
DELISTED
Exact Sciences
EXAS
$8.22M 0.52%
105,578
-12,681
-11% -$1.12M
VEEV icon
71
Veeva Systems
VEEV
$37.4B
$8.12M 0.51%
31,796
-14,447
-31% -$4.2M
JPM icon
72
JPMorgan Chase
JPM
$950B
$8.08M 0.51%
51,000
+21,000
+70% +$3.45M
ADBE icon
73
Adobe
ADBE
$105B
$8.02M 0.51%
14,137
+8,352
+144% +$5.22M
MASS icon
74
908 Devices
MASS
$364M
$8.02M 0.51%
309,833
+22,018
+8% +$648K
AMZN icon
75
Amazon
AMZN
$2.96T
$7.95M 0.5%
47,700
+11,040
+30% +$1.89M
1 2
3
4 5

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Nicholas Investment Partners held 221 positions worth $1.58B, up 15% from $1.37B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Nicholas Investment Partners deployed $71.1M of net new capital in Q4 2021, opening 32 new positions and adding to 92 existing holdings. Its largest new stake was P3 Health Partners: 21,075 shares worth $7.42M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 36% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Ginkgo Bioworks, an estimated $8.89M trimmed.

  • Nicholas Investment Partners's largest Q4 2021 buy was P3 Health Partners: 21,075 shares worth $7.42M.
  • Nicholas Investment Partners added most to Ascendis Pharma A/S in Q4 2021, an estimated $12.6M increase.
  • Nicholas Investment Partners's biggest Q4 2021 reduction was Ginkgo Bioworks, cutting an estimated $8.89M.
  • Nicholas Investment Partners fully exited Amyris Inc. in Q4 2021, selling an estimated $13M.
  • Nicholas Investment Partners's ten largest holdings make up 18% of its $1.58B portfolio in Q4 2021.
  • Nicholas Investment Partners opened 32 new positions and closed 27 in Q4 2021.
  • Nicholas Investment Partners's portfolio value rose 15% quarter-over-quarter to $1.58B.

Based on Nicholas Investment Partners's 13F filing for Q4 2021, filed 14 Feb 2022.